Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,234 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumours
Interventions
ODM-212
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • St Louis, Missouri + 5 more
Conditions
Advanced Solid Tumor
Interventions
VX-984 120 mg + PLD 40 mg/m^2, VX-984 240 mg + PLD 40 mg/m^2, VX-984 480 mg + PLD 40 mg/m^2, VX-984 720 mg + PLD 40 mg/m^2
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee + 2 more
Conditions
Healthy
Interventions
Ad26.RSV.preF 5*10^10 vp, Ad26.RSV.preF 1*10^11 vp, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Conditions
Malignant Solid Tumor
Interventions
GEN1055, Pembrolizumab, Standard Chemotherapy
Biological · Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
STX-241
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Healthy
Interventions
AZD5847, Placebo to AZD5847
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
Interventions
IK-930, Osimertinib
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 5 more
Conditions
Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
Interventions
MBQ-167
Drug
Lead sponsor
MBQ Pharma
Industry
Eligibility
21 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Beverly Hills, California • Sarasota, Florida • Nashville, Tennessee
Terminated Phase 1Phase 2 Interventional Results available

First-in-Human Study of TAK-280 in Participants With Solid Tumors

NCT05220098
Conditions
Unresectable Locally Advanced or Metastatic Cancer
Interventions
TAK-280
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • San Francisco, California • Minneapolis, Minnesota + 6 more
Conditions
Neuropathic Pain
Interventions
LY4286533, placebo
Drug
Lead sponsor
4E Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Conditions
Epileptic Encephalopathy
Interventions
S230815- Starting dose A, S230815- Dose B, S230815- Dose C, S230815- Dose D
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
2 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Orange, California • Boston, Massachusetts • Rochester, New York + 2 more
Conditions
Solid Tumor
Interventions
BNT142
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Baltimore, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania + 3 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

NCT05089630
Conditions
Cytomegalovirus Infections
Interventions
Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline solution)
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
18
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 15 more
Conditions
Renal Cell Carcinoma (Kidney Cancer)
Interventions
111In-XYIMSR-01
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S, Single dose, BBT-401-1S, Multiple doses, Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
BAY2315497 Injection, Darolutamide(BAY1841788)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
New Orleans, Louisiana • Omaha, Nebraska • New York, New York
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Conditions
Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
Interventions
ADCT-701
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Healthy Participants
Interventions
Placebo, XTMAB-16 2 mg/kg, XTMAB-16 4mg/kg
Drug
Lead sponsor
Xentria, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash
Drug · Other
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Conditions
Uveal Melanoma, Metastatic
Interventions
4.7 microCi 225Ac-MTI-201, 9.5 microCi of 225Ac-MTI-201, 19 microCi of 225Ac-MTI-201, 38 microCi of 225Ac-MTI-201, 76 microCi of 225Ac-MTI-201, 152 microCi of 225Ac-MTI-201, 254 microCi of 225Ac-MTI-201, 424 microCi of 225Ac-MTI-201, 564 microCi of 225Ac-MTI-201, 750 microCi of 225Ac-MTI-201, 998 microCi of 225Ac-MTI-201, 1327 microCi of 225Ac-MTI-201
Drug
Lead sponsor
Modulation Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Solid Tumors, Urothelial Carcinoma
Interventions
GEN1106
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
New Haven, Connecticut • Lake Success, New York • Myrtle Beach, South Carolina + 2 more
Conditions
Metastatic HR+/HER2- Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

NCT03529773
Conditions
Respiratory Tract Infections
Interventions
Formulation A, Formulation B, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
40
States / cities
Mobile, Alabama • Anaheim, California • La Mesa, California + 30 more